European Journal of Haematology

Article	Citations
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect	122
	67
	61
Issue Information	58
Augmenter of liver regeneration promotes drug resistance of acute lymphoblastic leukemia through the alteration of mitochondrial functions and the inhibition of the mitochondrial apoptosis pathway	58
The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review	56
Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia	43
Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma	38
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)‐T cell therapy in patients with hematological malignancy	36
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes	32
Impact of Gut Microbiota and Inflammatory Cytokines on Immune Thrombocytopenia	32
Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma	29
Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization	28
Salvage Therapies After Anti‐BCMA CAR‐T Failure in Patients With Multiple Myeloma: A Meta‐Analysis of Response Rates	27
Vaccination in Multiple Myeloma: Challenges and Strategies	26
Plasma microbial cell‐free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia	24
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma	24
Pubertal Assessment and Growth in Patients With Hemoglobinopathies: A Longitudinal Multicenter Study on the Association With Ferritin Levels	22
Effects of tertiary palliative care on the pattern of end‐of‐life care in patients with hematologic malignancies in Korea	22
Issue Information	21
Enhancing thalassemia gene carrier identification in non‐anemic populations using artificial intelligence erythrocyte morphology analysis and machine	20
Flow cytometry for comprehensive assessment of platelet functional activity in response to ADP stimulation	19
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial	19
Utilization and outcome disparities in allogeneic hematopoietic stem cell transplant in the United States	19
Efficacy and Tolerance of Cladribine for Non‐Langerhans Cell Histiocytosis	19

Myeloproliferative Neoplasms and Dementia Risk: A Population‐Based Cohort Study	18
Bridging Trials and Real Life in Fixed‐Duration BTKi –Venetoclax for CLL : A Delphi‐Enhanced Synth	18
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk underg	18
Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease during the Omicron wave in France	17
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes	17
Soluble MIC‐A, IPI, and response to treatment strongly predict survival in patients with germinal center diffuse large B cell lymphoma	17
Long‐term effectiveness of eculizumab: Data from the International PNH Registry	17
	17
Issue Information	17
Construction of Lymphoma Organoids and Applications in Tumor Microenvironment Research	16
From Rh Blood Group Antigen Antibody Testing to “Transfusionomics”	16
Transfusion requirements and complication rate in β‐thalassemia intermedia due to heterozygous β‐globin gene mutation and triplicated α‐globin genes	15
Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept	15
Are we ready for personalizedCAR‐Ttherapy?	15
Challenges and Solutions to Implementation of Chimeric Antigen Receptor Therapies in Acute Myeloid Leukemia	15
Venous thromboembolism prophylaxis in hospitalized sickle cell disease and sickle cell trait patients	15
BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study	14
Relationship between hemoglobin, hemolysis, and transcranial Doppler velocities in children with sickle cell disease: Results from a long‐term natural history study in Italy in the era of multimodal t	14
Genome‐Wide Meta‐Analysis of 1 896 991 Individuals Identifies 31 Novel Risk Loci for Iron Deficiency Anemia	14
Isatuximab, Carfilzomib, and Dexamethasone Combined With Late Autologous Stem Cell Transplantation: A Synergistic Strategy for First Relapse Multiple Myeloma	14
Antiemetic prophylaxis regimens in haematologic malignancies patients undergoing a hematopoietic stem cell transplantation. Which is the best standard of care? A systematic review	14
Issue Information	14
Efficacy of CD38 ‐Targeted Therapy in Severe, Multi‐Agent Refractory Immune Thrombocytopenia: A Case Series	14
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study	14
Momelotinib Is Effective in Treatment for VEXAS Syndrome: Two Cases Within the AGMT Austrian Myeloid Registry	13
Home‐Based Daratumumab in Patients With Multiple Myeloma	13
Comparative Effectiveness and Safety of PI‐Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT‐MM	13
HyperCVAD versus pegaspargase‐containing regimens for Hispanic adults with newly diagnosed B‐cell acute lymphoblastic leukemia	13
Epigenetics and In Silico Transcriptome Analysis of Pediatric Acute Myeloid Leukemia	13
	13
Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine	13
The Amyloidosis Intersection: Dual Amyloid Types in a Single Host	13
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies	13
Specialist Palliative Care and the Use of Healthcare Services Among Patients With Multiple Myeloma: A Nationwide Cohort Study	12
Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia	12
Issue Information	12
Issue Information	12
Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma	12
A post hoc analysis of PROTECT VIII Kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A	12
Long‐term remission in a patient with relapsed Richter's transformation treated with CD19‐directed chimeric antigen‐receptor T‐cells after allogeneic stem cell transplantation	12
Persistent decreased bone marrow CD3+CD56+ T lymphocytes are inversely associated with mature granulocytes in myelodysplastic syndromes	12
Outcomes of COVID‐19 hospitalizations in patients with sickle cell disease: A nationwide analysis	12
Estrogen‐based hormonal therapy and the risk of thrombosis in COVID‐19 patients	12
T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions	12
Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis	12
Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post‐Transplantation Cyclophosphamide Based GVHD	12
Clinical and Laboratory Indicators of Pediatric Leukemia and Neuroblastoma in Musculoskeletal Presentations: A Retrospective Study From a Resource‐Limited Setting	11
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population	11
Efficacy and Safety of the C5 Inhibitor Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta‐Analysis	11
Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis	11

Sequencing and combination of currentsmall‐moleculeinhibitors for chronic lymphocytic leukemia: Where is the evidence?	11
Hematological and genetic profiles of persons with co‐inherited heterozygous β‐thalassemia and supernumerary α‐globin genes	11
Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program	11
Platelet kinetics in patients with chronic immune thrombocytopaenia treated with thrombopoietin receptor agonists	11
Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma	11
Relationships between T‐lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study	11
The incidence, complications, and treatment of iron deficiency in pregnancy	11
Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis	10
STAT3 / STAT5 Mutations Predict Shorter Overall Survival in Patients with Plasma Cell Myeloma	10
Precision Anticoagulation: The Imperative Usage of DOACs for Disease‐Specific Risk Stratification in MPNs	10
Three cases of late‐onset post CAR‐T therapy isolated CNS relapse in R/R large B‐cell lymphoma	10
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study	10
Autologous stem cell transplantation in multiple myeloma patients over 70 years: A GIMEMA Lazio Working Group experience in a retrospective case–control study	10
Real‐World Experience With a ZUMA ‐1 Cohort 4 Adopted Approach to CRS and	10
Updating Efficacy of First‐Line Treatments for Chronic Lymphocytic Leukemia: Indirect Comparisons Based on Recent Data Favor the Combination of Acalabrutinib Plus Obinutuzumab	10
Impact of Preanalytical Sample Preparation on the Recovery Rate of Cryopreserved Allogeneic Hematopoietic Stem Cells	10
Asciminib in Advanced‐Line Treatment of Chronic Myeloid Leukemia	10
Primary Cutaneous B‐Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management	10
Adherence and Quality of Life in Adult Patients With Haemophilia A, Haemophilia B and Von Willebrand Disease: A National Cross‐Sectional Survey	10
Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition	9
Salvage Therapy in Multiple Myeloma With Prior T‐Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide	9
	9
Clinical outcomes of patients referred for asymptomatic neutropenia: A focus on racial disparities in hematology	9
	9
	9
Long‐term haematological response and maintained immunological function after laparoscopic subtotal splenectomy in patients with hereditary spherocytosis	9
	9
Survival and risk of vascular complications in myelofibrosis—A population‐based study from the Swedish MPN group	9
	9
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial	9
Impact of Modern Strategies for Graft‐Versus‐Host Disease Prophylaxis on Relapse Risk in Matched‐Sibling or Unrelated Donor Hematopoietic Cell Transplantation: A Systematic Review and Meta‐Analysis of	9
Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on theEORTC‐Dutchlate effects cohort‐linked data	9
A precision‐based exercise program for patients with multiple myeloma	9
Central Venous Access Device Complications in Children With Leukemia: A Systematic Review and Meta‐Analysis	9
Global prevalence of anemia among women of reproductive age, 2000–2019	9
Chimeric antigen receptor T cells for acute myeloid leukemia	8
Patient‐Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non‐Transfusion‐Dependent β‐Thalassemia Treated in the BEYOND	8
Pathogenic Mechanisms of Systemic Mastocytosis: Unraveling the Genetic Complexity, Bone Marrow Microenvironment, and Clinical Challenges	8
CD48 Is a Robust Marker and a Useful Addition for Assessment of Measurable Residual Disease in T‐Cell Acute Lymphoblastic Leukemia	8
Phenotype of BTK‐lacking myeloid cells during prolonged COVID‐19 and upon convalescent plasma	8
Outcomes in Kaposi's sarcoma‐associated herpesvirus ‐associated primary effusion lymphoma and multicentric Castleman's	8
Pattern of use and clinical outcomes with rIX‐FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real‐world study	8
Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning	8
	8
Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction	8
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir‐exposed CMV‐free population receiving PTCy	8
Interferon gamma regulates a complex pro‐survival signal network in chronic lymphocytic leukemia	8
Νοvel Therapies in High‐Risk Myelodysplastic Syndromes	8
Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review	8
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study	8
Trends and in‐hospital cardiac complications in patients with atrial fibrillation undergoing allogeneic stem cell transplant: A National Inpatient Sample analysis (2002–2019)	8
15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic le	8
Hematopoietic cell transplantation for telomere biology diseases: A retrospective single‐center cohort study	8
ProGraME: A novel flow cytometry algorithm for the diagnosis of low‐risk myelodysplastic syndromes in patients with cytopenia	8
Development and validation of the sickle cell stress scale‐adult	8
Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study	8
The applicability of the central line‐associated bloodstream infection ( CLABSI ) criteria for the evaluation of bacteremia episodes in pediatric onc	8
Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia	8
Optimizing Pediatric Tunneled Central Venous Catheter Placement: A Height‐Based Approach for Precise Length Determination	8
Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry	7
Endothelial Cells in Lymphomas	7
Appropriateness of inpatient intravenous iron therapy in a Swiss tertiary care hospital	7
Clinical Management of Persistent Hypereosinophilia	7
Relevance, Risks, and Benefits of Early‐Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023	7
Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management	7
Issue Information	7
Issue Information	7
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care	7
The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta‐analysis	7
Core Needle Biopsies in Patients With Lymphoproliferative Malignancies: An Observational Single‐Center Cohort Study	7
Validation of the GATMO score in predicting non‐relapse mortality following hematopoietic cell transplant in multiple myeloma patients	7
Bone marrow expression of CD68/CD163 macrophages, IL‐17 and FOXP3 cells in aplastic anemia and their relation to prognosis	7
Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemoth	7
Correction to “Global and Regional Burden of Vaccine‐Induced Thrombotic Thrombocytopenia, 1969–2023: Comprehensive Findings With Critical Analysis of the International Pharmacovigilance Database”	7
A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose	7
Screening for multidrug‐resistant organisms in high‐risk hospitalized patients with hematologic diseases	7
Whole Blood Transcriptomic Analysis of Sickle Cell Trait	7
Fetal Hemoglobin Decrease During Voxelotor Treatment	7
Risk‐based and individualised management of bleeding and thrombotic events in adults with primary immune thrombocytopenia (ITP)	7
Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 Patients	7

Treatment of Refractory Monoclonal Immunoglobulin Deposition Disease With BCMA Bispecific Antibody	7
Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real‐world retrospective study	7
Clonal Progression and Leukemic Transformation of a TP53 Mutated Post‐Polycythaemia Vera Myelofibrosis	7
Featured Cover	7
Musculoskeletal Symptoms and Misdiagnoses in Children With Acute Myeloid Leukaemia: A Nationwide Cohort Study	7
Efficacy of conventional‐dose cytarabine, idarubicin and thioguanine versus intermediate‐dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long‐term results of the p	7
Exercise in newly diagnosed patients with multiple myeloma: A randomized controlled trial of effects on physical function, physical activity, lean body mass, bone mineral density, pain, and quality of	7
JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms	7
Relationship Between Daily Step Count, Biological Markers, and Clinical Outcomes in Patients With Sickle Cell Anemia: A Cross‐Sectional Study	7
Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis	7
Cost‐Effectiveness of Venetoclax‐Based Treatment in Treatment‐Naïve Fit Patients With CLL Without TP53	7
	7
Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients	7
The Role of SAMHD1 in Viral Resistance and Transduction Efficiency Challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives	7
Busulfan and cyclophosphamide‐based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion‐dependent thalassem	7
Resveratrol and tetrahydroisoquinoline effects on neutrophil sensitivity to NETosis formation in low‐risk essential thrombocythemia patients	6
Distribution of ABO /Rh Blood Types Across Childhood Leukemia Subtypes: A Retrospective Cohort Study of 540 Pediatric Patients	6
Vaccination Uptake in Adults Post‐Haematopoietic Stem Cell Transplantation for B‐Cell Malignancies	6
Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients	6
Issue Information	6
The role of oral iron in the treatment of adults with iron deficiency	6
The current challenges faced by people with hemophilia B	6
Effectiveness of progressive moderate‐vigorous intensity elastic resistance training on quality of life and perceived functional abilities in people with hemophilia: Secondary analysis of a randomized	6
Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults	6
Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol	6
Increased Non‐Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan‐Based Regimen	6
A Clinical Prediction Model for Inadequate Hemoglobin Response After Red Blood Cell Transfusion	6
The impact of hematology electronic consultations on the management of iron deficiency	6
Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens	6
Treatment of Critical Bleeds in Patients With Immune Thrombocytopenia: A Systematic Review	6
Cytogenetic and molecular characteristics and outcomes of adult patients with early T‐cell precursor acute lymphoblastic leukemia	6
	6
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents	6
Recombinant factor IX Fc for the treatment of hemophilia B	6
Harnessing Polygenic Risk Scores to Refine Venous Thromboembolism Risk Stratification	6
Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups	6
Evaluation of soluble P‐selectin as a predictive biomarker in acute symptomatic pulmonary embolism: Insights from a prospective observational study	6
Comparison of telomere length in patients with bone marrow failure syndromes and healthy controls	6
Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti‐Myeloma Therapies	6
Tandem bispecific CD123/CLL‐1 CAR‐T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia	6
Role of Nek2 and Hec1 in HTLV ‐1‐Infected T‐Cell Lines	6
Treatment horizon in multiple myeloma	6
Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T‐cell therapy	6
The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center	6
Venetoclax Combined With FLAG‐IDA in Refractory or Relapsed Acute Myeloid Leukemia	6
A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia	6
Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies	6
ABO Blood Type and Short‐Term Mortality in Patients With Infection‐Associated Disseminated Intravascular Coagulation	6
First‐Line Treatment of IGHV ‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens	6
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective analysis on consecutive patients fr	6
Childhood autoimmune hemolytic anemia: A scoping review	6
Treatment Free Remission (TFR) in Chronic Phase‐Chronic Myeloid Leukemia (CP‐CML): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecula	5
Epidemiology and clinical outcomes of light‐chain amyloidosis in Sweden: A nationwide population‐based study	5
Hyper‐CVAD and Modified CALGB‐10403 Regimens in Adult Patients With Philadelphia‐Negative Acute Lymphoblastic Leukemia: A Comparative Study	5
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database	5
The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review	5
Development of the Cold Agglutinin Disease Symptoms and Impact Questionnaire (CAD‐SIQ)	5
Biological Findings and Clinical Outcomes in Patients Treated With R‐CHOP Plus High‐Dose Methotrexate as First‐Line Therapy in Large B‐Cell Lymphoma With Testis Involvement	5
Marked hyperferritinemia in critically ill cancer patients	5
Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic	5
Herpes zoster prophylaxis with low‐dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation	5
Issue Information	5
Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma	5
Nivolumab Maintenance for Aggressive B‐Cell Lymphoma in Remission After First Line Therapy: A Phase 2 Clinical Trial	5
Correction to “Venetoclax‐Based Therapy for Relapsed or Refractory Acute Myeloid Leukaemia Following Intensive Induction Chemotherapy”	5
Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies	5
Issue Information	5
Cardiovascular Challenges in Chronic Lymphocytic Leukemia ( CLL ) Patients Undergoing Bruton Tyrosine Kinase ( BTK	5
Cytokine expression in pediatric patients with immune thrombocytopenia (ITP) in different phases of disease	5
Assessing the Burden of C5 Inhibitor Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria	5
Significance of Pre‐ and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core‐Binding Factor Acute Myeloid Leukemia	5
Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation	5
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation	5
Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia	5
Differences in patient‐reported outcomes (PROs) by disease severity in light chain (AL) amyloidosis	5
Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients	5
Apheresis collection of mononuclear cells for chimeric‐antigen receptor therapies	5
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation	5
Imaging in Plasma‐Cell Neoplasms: Italian Experts’ Recommendations	5
ORPHEE: A Real‐World Study on rIX‐FP Prophylaxis Use in Adolescent/Adult Patients With Hemophilia B	5
Health‐related quality of life in patients with steroid‐refractory acute graft‐versus‐host disease	5
	5
Immunophenotyping for the Assessment of Asymptomatic Lymphocytosis: A Retrospective Analysis and National Survey	5
Issue Information	5
CLLAF SCORE—A New Risk Score for Predicting Atrial Fibrillation in Treatment‐Naive CLL Patients Initiating First‐ and Second‐Generation BTK Inhibitor Therapy	5
Allogeneic hematopoetic stem cell transplant for patients with refractory T‐Cell lymphomas	5
LP2, a stable lanthipeptide derived from cAng‐(1‐7), exerts myeloprotective action in mice	5
Rate of MGUS Progression to Haematological Malignancies: A Systematic Review	5
Excess Mortality of Warm Autoimmune Haemolytic Anaemia: Unrecognised and Unmet Real‐World Needs	5
Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia	5
Iron Deficiency in the Presence of Anemia and Inflammation—A Sex‐Specific Cross‐Sectional Study	5
Effects of anti‐Xa activity monitoring on the outcome of high‐risk pregnancies treated with a prophylactic dose of low‐molecular‐weight heparin	5
Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings	5
Real‐World Evidence of Crizanlizumab Showing Reductions in Vaso‐Occlusive Crises and Opioid Usage in Sickle Cell Disease	5
Further Reflections on 6‐MP Adherence and Habit Strength: The Impact of Dose Adjustment Complexity and Caregiver Burden	5